|
|
Volumn 23, Issue 2, 2015, Pages 217-218
|
|
Glybera's second act: The curtain rises on the high cost of therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BLOOD CLOTTING FACTOR;
GENE THERAPY AGENT;
PARVOVIRUS VECTOR;
SOFOSBUVIR;
ALIPOGENE TIPARVOVEC;
BLOOD CLOTTING INHIBITOR;
ECULIZUMAB;
ADENO ASSOCIATED VIRUS 1;
BREAST CANCER;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DISEASE SEVERITY;
DRUG COST;
DRUG RESEARCH;
EDITORIAL;
ENZYME REPLACEMENT;
FUNDING;
GENE THERAPY;
HEALTH CARE COST;
HEALTH CARE DELIVERY;
HEALTH INSURANCE;
HEMOPHILIA;
HEPATITIS C;
HUMAN;
HYPERLIPOPROTEINEMIA TYPE 1;
VIRAL GENE DELIVERY SYSTEM;
VIRAL GENE THERAPY;
ECONOMICS;
ADENO ASSOCIATED VIRUS;
BLEEDING;
DRUG APPROVAL;
REIMBURSEMENT;
UNITED STATES;
DRUG COSTS;
GENETIC THERAPY;
HEALTH CARE COSTS;
HUMANS;
|
|
EID: 84961291885
PISSN: 15250016
EISSN: 15250024
Source Type: Journal
DOI: 10.1038/mt.2014.248 Document Type: Editorial |
|
Times cited : (42)
|
|
References (3)
|
